Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

AIDS

Volumn 20, Issue 10, 2006, Pages 1391-1399

  Walker, A S ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Africa; Antiretroviral therapy; Nucleoside nucleotides

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; RNA, VIRAL; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; ZIDOVUDINE; ZIMBABWE;

EID: 33745450105     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000233572.59522.45     Document Type: Article

References (25)

1. World Health Organization. Scaling up antiviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization; 2002.
2. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple nucleoside regimens versus efavirenz containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
3. Cuzin C, Pugliese P, Bugnon F, Delpierre C, Cua E, Billaud E, et al. Triple nucleoside reverse transcriptase inhibitor- versus non-nucleoside reverse transcriptase inhibitor- containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Med 2005; 6:388-395.
4. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Second IAS Conference on HIV Pathogenesis and Treatment, Paris, 2003.[abstract 43].
5. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. XI Conference on Retroviruses and Opportunistic Infections, 2004.[abstract 51].
6. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al., for the ESS30009 Study. Early virologic non-response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
7. Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, et al. 24-week efficacy and resistance profile of a zidovudine/lamivudine/tenofovir DF combination therapy in antiretroviral- naïve patients. International HIV Drug Resistance workshop, Quebec, 2005.
8. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:947-949.
9. Pillay D, Cane PA, Shirley J, Porter K. Detection of drug resistance in HIV primary infection within the UK. AIDS 2000; 14:906-908.
10. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-57.
11. Gale CV, Myers R, Tedder RS, Williams IG, Kellam P. Development of a novel human immunodeficiency virus type 1 subtyping tool, Subtype Analyzer (STAR): analysis of subtype distribution in London. AIDS Res Hum Ret 2004; 20:457-464.
12. Arnemyia T. Regression analysis when the dependent variable is truncated Normal. Econometrica 1973; 41:997-1016.
13. Charalambous S, Stenson A, Fielding K, Pemba L, Whetham J, Dwadwa T, et al. 6-month outcomes among HIV-infected individuals starting antiretroviral therapy in South Africa. The Third IAS Conference on HIV Pathogenesis and Treatment, 2005. [abstract MoPe11.2C41].
14. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
15. Moore A, Kirk O, Johnson A, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452-461.
16. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-2567.
17. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155-1163.
18. Pillay D. HIV viral load: the myth of the undetectable? Rev Med Virol 2002; 12:391-396.
19. Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/ efavirenz: 12-week results from a randomized trial. AIDS 2005; 19:1183-1188.
20. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
21. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller M, et al., and the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
22. Ssali F, Munderi P, Reid A, Walker AS, Stohr W, Gilks C, on behalf of the DART Trial. Severe anaemia and associated risk factors following initiation of ZDV-containing regimens in adults with HIV infection in Africa within the DART trial. XII Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 2005 [abstract 24].
23. White KL, Margot NA, Ly JK, Chen JM, Ray AS, Pavelko M, et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005; 19:1751-1760.
24. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kutitzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Fall. Top HIV Med 2005; 13:125-131.
25. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-1250.